Indication

KRAS G13D

1 clinical trial

1 product

Clinical trial

First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Status: Recruiting, Estimated PCD: 2026-11-01

Product